Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts

详细信息    查看全文

• 作者：Yimin Qian ; Matthew Hamilton ; Achyutharao Sidduri ; Stephen Gabriel ; Yonglin Ren ; Ruoqi Peng ; Rama Kondru ; Arjun Narayanan ; Terry Truitt ; Rachid Hamid ; Yun Chen ; Lin Zhang ; Adrian J. Fretland ; Ruben Alvarez Sanchez ; Kung-Ching Chang ; Matthew Lucas ; Ryan C. Schoenfeld ; Dramane Laine ; Maria E. Fuentes ; Christopher S. Stevenson ; David C. Budd
• 刊名：Journal of Medicinal Chemistry
• 出版年：2012
• 出版时间：September 13, 2012
• 年：2012
• 卷：55
• 期：17
• 页码：7920-7939
• 全文大小：713K
• 年卷期：v.55,no.17(September 13, 2012)
• ISSN：1520-4804

文摘

Lysophosphatidic acid is a class of bioactive phospholipid that mediates most of its biological effects through LPA receptors, of which six isoforms have been identified. The recent results from LPA1 knockout mice suggested that blocking LPA1 signaling could provide a potential novel approach for the treatment of idiopathic pulmonary fibrosis. Here, we report the design and synthesis of pyrazole- and triazole-derived carbamates as LPA1-selective and LPA1/3 dual antagonists. In particular, compound 2, the most selective LPA1 antagonist reported, inhibited proliferation and contraction of normal human lung fibroblasts (NHLF) following LPA stimulation. Oral dosing of compound 2 to mice resulted in a dose-dependent reduction of plasma histamine levels in a murine LPA challenge model. Furthermore, we applied our novel antagonists as chemistry probes and investigated the contribution of LPA1/2/3 in mediating the pro-fibrotic responses. Our results suggest LPA1 as the major receptor subtype mediating LPA-induced proliferation and contraction of NHLF.